Medallion Increases Private Placement to $250,000 – Closes $150,000 Tranche (December 11th, 2014)

Medallion Resources Ltd. - $MDL:CA |

Medallion Increases Private Placement to $250,000 – Closes $150,000 Tranche


Vancouver, BC – Medallion Resources Ltd (TSX-V: MDL; OTCQB: MLLOF – “Medallion” or the “Company”), today announced that it has closed a first tranche of $150,000 of its $200,000 non-brokered private placement announced November 9, 2014. The Company also announced that it is increasing the private placement by an additional $50,000.   The terms of the placement now call for the issue of up to 5,000,000 units (each a “Unit”) at $0.05 per Unit for gross proceeds of up to $250,000 (the “Offering”). Each Unit consists of one common share and one-half of a transferable common share purchase warrant (a “Warrant”). Each whole Warrant is exercisable to acquire one common share at an exercise price of $0.20, for a period of 3 years from closing of the Offering (“Closing Date”).

The Company issued 3,000,000 Units pursuant to the first tranche of the Offering and expects to close the balance of the placement, representing 2,000,000 Units for a total of $100,000 prior to year end. In this tranche, Medallion Directors and Officers subscribed for Units totally $95,000, which includes $33,000 of subscription funds received from the sale of 660,000 shares of Medallion, through the facilities of the Exchange. All securities issued to purchasers under the first tranche are subject to a four-month hold period expiring April 9, 2015, pursuant to securities legislation and the policies of the Exchange. No finder’s fees or finder’s options were issued on the closing of this first tranche.

Medallion has agreed to pay a finders’ fee of 8% of the gross proceeds of certain subscriptions, payable in cash or Units, at the discretion of the finder, and will grant finders’ options equal to 8% of the Units sold by qualified finders. Each finder’s option shall be exercisable to acquire one common share of the Company at an exercise price of $0.05 per share, for a period of 24 months from the Closing Date. The proceeds of the Offering will be used for lab-scale testing of monazite processing for potential customers, monazite feedstock acquisition activities, and working capital.

All securities issued to purchasers and finders under the Offering will be subject to a four-month hold period from the Closing Date, pursuant to securities legislation and the policies of the Exchange. The securities offered have not been nor will they be registered under the United States Securities Act of 1933, as amended, or state securities laws, and may not be offered or sold in the United States or to an account for the benefit of US persons, absent such registration or an exemption from registration. This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities in the United States or in any jurisdiction in which such offer, sale, or solicitation would be unlawful.

About Medallion Resources

Medallion Resources is focused on the opportunity for low-cost, near-term, rare-earth production by exploiting the mineral monazite. Monazite is a rare-earth phosphate that is available as a by-product from existing mining and mineral-sands sources, principally in the Indian Ocean basin. Rare earths are used in critical components for virtually all computing and mobile electronic products, as well as wind turbines, electric and hybrid vehicles, and strategic defense systems. Medallion is committed to following best practices and accepted international standards in all aspects of mineral processing and the safe management of waste materials. More about Medallion (TSX-V: MDL; OTCQB: MLLOF; Frankfurt: MRD) can be found at

Donald Lay, President & CEO at +1.604.681.9558 or

Kam Thindal, Hamza Thindal Capital Corp. at +1.604-566-9236


Medallion management takes full responsibility for content and has prepared this news release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Some of the statements contained in this release are forward-looking statements, such as statements relating to completion of extraction processing tests, and estimates and statements that describe Medallion’s future production and financing plans, objectives or goals, including words to the effect that Medallion or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties, including the risks inherent in completing laboratory-scale processing tests and applying the results to full-scale production and other risks outlined in the Company’s management discussions and analysis of financial results. Actual results in each case could differ materially from those currently anticipated in these statements. Such risks include expectations that may be raised by discussing potential business, acquisitions or development plans. Also, in order to proceed with Medallion’s plans, additional funding will be necessary and, depending on market conditions, this funding may not be forthcoming on a schedule or on terms that facilitate Medallion’s plans.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:



Symbol Last Price Change % Change










World Economic Forum at Davos 2019 - Dr Oliver Krause Founder Untitled Inc Part 2

Matt Bird sits down with Dr Oliver Krause, Founder Untitled Inc, in part 2 of this 2 part interview at the World Economic Forum at Davos 2019

Emerging Growth

IMV Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.